<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-33 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-33</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-33</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-4.html">extraction-schema-4</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <p><strong>Paper ID:</strong> paper-b77b6ccb10453d3b6e4c4e2ac80b939df211193a</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/b77b6ccb10453d3b6e4c4e2ac80b939df211193a" target="_blank">Treatment of Advanced Metastatic Melanoma</a></p>
                <p><strong>Paper Venue:</strong> Dermatology Practical & Conceptual</p>
                <p><strong>Paper TL;DR:</strong> This review will analyze the current therapeutic tools adopted for the treatment of metastatic melanoma patients, and focus on the latest results obtained by novel treatments (checkpoint inhibitors and targeted therapies) which can be used in the clinical daily practice.</p>
                <p><strong>Paper Abstract:</strong> The introduction in clinical practice of new drug compounds both targeted therapies anti-BRAF and checkpoint inhibitors have largely improved our potential to manage advanced metastatic melanoma patients. This has led to a significant improvement in terms of response rates and particularly in the overall survival (OS). The long-term results of trials with follow-up data of patients treated with targeted or immunotherapies reported median OS rates around 24 months, with 5-year survival rates around 35-40%. As to the drugs currently available and reimbursed by the Italian National Health System, 3 combinations of anti-BRAF/anti-MEK inhibitors are available (dabrafenib/trametinib, vemurafenib/cobimetinib and the most recently introduced encorafenib/binimetinib). As for checkpoint inhibitors, first line immunotherapy is represented by anti-PD1 blockers (nivolumab and pembrolizumab), whilst the anti-CTLA-4 ipilimumab can be used as second line immunotherapy. The decision-making factors that define the best treatment approach in stage IV patients with metastatic melanoma include the mutation pattern, performance status, high/low tumor load, brain metastases, progression pattern (low/fast), and availability of clinical trials. This review will analyze the current therapeutic tools adopted for the treatment of metastatic melanoma patients. It will then focus on the latest results obtained by novel treatments (checkpoint inhibitors and targeted therapies) which can be used in the clinical daily practice.</p>
                <p><strong>Cost:</strong> 0.021</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e33.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e33.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KEYNOTE-006 (stop-24mo analysis)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>KEYNOTE-006: Pembrolizumab versus ipilimumab in advanced melanoma (post-hoc 5-year results including patients who stopped after 24 months)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Phase 3 randomized trial of pembrolizumab (10 mg/kg q2w or q3w) versus ipilimumab in advanced melanoma; includes a protocol-permitted cohort of patients who stopped pembrolizumab after 24 months with reported outcomes after treatment interruption, stratified by response category.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>KEYNOTE-006</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_agent</strong></td>
                            <td>pembrolizumab</td>
                        </tr>
                        <tr>
                            <td><strong>melanoma_setting</strong></td>
                            <td>advanced/metastatic melanoma (previously untreated in first-line comparison vs ipilimumab)</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_duration_protocol</strong></td>
                            <td>Patients could stop pembrolizumab after 24 months per protocol (analysis performed on patients who stopped at 24 months).</td>
                        </tr>
                        <tr>
                            <td><strong>actual_median_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_categories_assessed</strong></td>
                            <td>CR, PR, SD (responses at time of treatment interruption were used to stratify outcomes)</td>
                        </tr>
                        <tr>
                            <td><strong>duration_differs_by_response</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>response_adapted_strategy</strong></td>
                            <td>No explicit response-adapted stopping in the randomized comparison; the reported analysis describes outcomes after protocol-specified stopping at 24 months, with outcomes stratified by response at stop.</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_duration</strong></td>
                            <td>After a median follow-up of 34.2 months from completion (for 103 patients who stopped at 24 months): estimated 24-month PFS from treatment interruption = 78.4% (overall); estimated 36-month OS = 93.8%. Overall trial metrics: median OS in combined pembrolizumab groups = 32.7 months vs 15.9 months with ipilimumab; median PFS = 8.4 months vs 3.4 months (p-values reported in paper). These stopping-data indicate durable disease control after 24 months of therapy in many patients, particularly responders.</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_response_category</strong></td>
                            <td>Estimated 24-month PFS after treatment interruption: CR = 85.4%; PR = 82.3%; SD = 39.9%. This shows markedly better durability after stopping for patients who achieved CR or PR versus those with SD.</td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_after_stopping</strong></td>
                            <td>For the 103 patients who stopped pembrolizumab at 24 months: 24-month PFS post-interruption = 78.4% (overall); by response at interruption: CR 85.4%, PR 82.3%, SD 39.9%; 36-month OS = 93.8% (overall).</td>
                        </tr>
                        <tr>
                            <td><strong>safety_by_duration</strong></td>
                            <td>No toxicity breakdown by duration after stopping is reported; overall grade 3-5 treatment-related adverse events in pembrolizumab groups were reported as 13.3% and 10.1% (for the two dosing schedules) but not linked to duration of therapy or to the stop-at-24-month subgroup in the text.</td>
                        </tr>
                        <tr>
                            <td><strong>discontinuation_rate_and_reasons</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_of_durations</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>optimal_duration_conclusion</strong></td>
                            <td>Authors note these data "pave the way" for the possibility of interruption of anti-PD1 treatment in responding patients after 2 years, especially for CR/PR, but do not establish a definitive, generalized stopping rule; conclusion presented as supportive but exploratory.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Treatment of Advanced Metastatic Melanoma', 'publication_date_yy_mm': '2021-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e33.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e33.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CheckMate 066 (5-year analysis)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>CheckMate 066: Nivolumab in previously untreated melanoma without BRAF mutation (5-year outcomes)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Phase 3 randomized trial of nivolumab versus dacarbazine in treatmentâ€‘naive, BRAF wild-type advanced melanoma with 5-year follow-up reporting long-term survival and outcomes stratified by response, including durable survival in complete responders.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Five-Year Outcomes with Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>CheckMate 066</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_agent</strong></td>
                            <td>nivolumab</td>
                        </tr>
                        <tr>
                            <td><strong>melanoma_setting</strong></td>
                            <td>advanced/metastatic melanoma (previously untreated, BRAF wild-type)</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_duration_protocol</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>actual_median_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_categories_assessed</strong></td>
                            <td>ORR, CR, PR, PFS, OS</td>
                        </tr>
                        <tr>
                            <td><strong>duration_differs_by_response</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_adapted_strategy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_duration</strong></td>
                            <td>5-year outcomes reported: ORR = 42% with nivolumab vs 14% with dacarbazine; 5-year OS = 39% with nivolumab vs 17% with dacarbazine; 5-year PFS rates reported as 28% vs 3%. The paper does not present a comparison of different planned treatment durations.</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_response_category</strong></td>
                            <td>Among patients treated with nivolumab who had a complete response (20% of nivolumab-treated patients), 88% (37 of 42) were alive at 5 years, indicating high long-term survival for CR patients.</td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_after_stopping</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>safety_by_duration</strong></td>
                            <td>Treatment-related adverse events were reported overall (11.7% in nivolumab group) but no toxicity stratified by duration or by stop rules is provided.</td>
                        </tr>
                        <tr>
                            <td><strong>discontinuation_rate_and_reasons</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_of_durations</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>optimal_duration_conclusion</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Treatment of Advanced Metastatic Melanoma', 'publication_date_yy_mm': '2021-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e33.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e33.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CheckMate 037 (final OS)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>CheckMate 037: Nivolumab versus investigator's choice chemotherapy in ipilimumab-refractory advanced melanoma (final overall survival report)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Phase 3 randomized open-label trial of nivolumab (3 mg/kg q2w) versus investigator-choice chemotherapy in patients with ipilimumab-refractory advanced melanoma, reporting response rates, median duration of response, and survival.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>CheckMate 037</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_agent</strong></td>
                            <td>nivolumab</td>
                        </tr>
                        <tr>
                            <td><strong>melanoma_setting</strong></td>
                            <td>advanced/metastatic melanoma (ipilimumab-refractory)</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_duration_protocol</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>actual_median_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_categories_assessed</strong></td>
                            <td>Objective response (ORR), duration of response, OS</td>
                        </tr>
                        <tr>
                            <td><strong>duration_differs_by_response</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_adapted_strategy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_duration</strong></td>
                            <td>Reported ORR 27% (nivolumab) vs 10% (chemotherapy). Median duration of response: 32 months for nivolumab vs 13 months for investigator-choice chemotherapy. Median OS: 16 months (nivolumab) vs 14 months (chemotherapy). These metrics describe durability of response but not different planned treatment durations.</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_response_category</strong></td>
                            <td>Duration of response is reported at group level (median 32 months for nivolumab) but not explicitly stratified into CR/PR/SD in this summary.</td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_after_stopping</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>safety_by_duration</strong></td>
                            <td>Fewer grade 3-4 treatment-related adverse events with nivolumab (14%) versus chemotherapy (34%); no data linking toxicity to cumulative duration of anti-PD1 exposure are reported.</td>
                        </tr>
                        <tr>
                            <td><strong>discontinuation_rate_and_reasons</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_of_durations</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>optimal_duration_conclusion</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Treatment of Advanced Metastatic Melanoma', 'publication_date_yy_mm': '2021-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e33.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e33.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CheckMate 067 (induction + maintenance schedules)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>CheckMate 067: Nivolumab plus ipilimumab versus nivolumab or ipilimumab alone in untreated advanced melanoma (combination induction then nivolumab maintenance schedule)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Large randomized phase 3 study comparing nivolumab+ipilimumab (induction 4 doses then nivolumab maintenance) versus nivolumab monotherapy or ipilimumab in previously untreated advanced melanoma, reporting PFS, OS, ORR and response rates including CR/PR.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>CheckMate 067</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_agent</strong></td>
                            <td>nivolumab (as monotherapy or in combination with ipilimumab)</td>
                        </tr>
                        <tr>
                            <td><strong>melanoma_setting</strong></td>
                            <td>advanced/metastatic melanoma (previously untreated)</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_duration_protocol</strong></td>
                            <td>Combination arm: induction nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 3 weeks for 4 doses, followed by nivolumab 3 mg/kg every 2 weeks (maintenance); exact planned total duration not specified in text.</td>
                        </tr>
                        <tr>
                            <td><strong>actual_median_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_categories_assessed</strong></td>
                            <td>ORR, CR, PR, PFS, OS; PD-L1 stratified analyses were performed (PD-L1 positive vs negative).</td>
                        </tr>
                        <tr>
                            <td><strong>duration_differs_by_response</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_adapted_strategy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_duration</strong></td>
                            <td>PFS: combination 11.5 months vs nivolumab 6.9 months vs ipilimumab 2.9 months. ORR: combination 57.6% vs nivolumab 43.7% vs ipilimumab 19%. 5-year OS: combination 52% vs nivolumab 44% vs ipilimumab 26%. The trial reports superior PFS/OS with combination in PD-L1 negative tumors; no prespecified comparison of fixed treatment durations vs stopping rules is reported.</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_response_category</strong></td>
                            <td>Complete response rates: combination 11.5%, nivolumab 8.9%, ipilimumab 2.2%. PD-L1 stratification: for PD-L1 positive tumors median PFS was 14.0 months with both nivolumab-plus-ipilimumab and nivolumab; for PD-L1 negative tumors PFS was 11.2 months with combination vs 5.3 months with nivolumab alone.</td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_after_stopping</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>safety_by_duration</strong></td>
                            <td>Grade 3-4 treatment-related adverse events: 59% (nivolumab+ipilimumab), 23% (nivolumab), 28% (ipilimumab); not reported by cumulative duration or after treatment cessation.</td>
                        </tr>
                        <tr>
                            <td><strong>discontinuation_rate_and_reasons</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_of_durations</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>optimal_duration_conclusion</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Treatment of Advanced Metastatic Melanoma', 'publication_date_yy_mm': '2021-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e33.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e33.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of anti-PD1 immunotherapy duration for melanoma patients, including treatment schedules, outcomes by response category, and comparisons of different duration strategies.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KEYNOTE-002</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>KEYNOTE-002: Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Randomized phase II trial of pembrolizumab (2 mg/kg or 10 mg/kg q3w) versus investigator-choice chemotherapy in ipilimumab-refractory advanced melanoma, reporting PFS and ORR; includes long-term (final post-hoc 5-year) ORR data.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_name</strong></td>
                            <td>KEYNOTE-002</td>
                        </tr>
                        <tr>
                            <td><strong>anti_pd1_agent</strong></td>
                            <td>pembrolizumab</td>
                        </tr>
                        <tr>
                            <td><strong>melanoma_setting</strong></td>
                            <td>advanced/metastatic melanoma (ipilimumab-refractory)</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_duration_protocol</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>actual_median_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_categories_assessed</strong></td>
                            <td>ORR, PFS</td>
                        </tr>
                        <tr>
                            <td><strong>duration_differs_by_response</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>response_adapted_strategy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_duration</strong></td>
                            <td>6-month PFS: pembrolizumab 2 mg/kg = 34%, 10 mg/kg = 38%, chemotherapy = 16%; final post-hoc 5-year ORR: 22% and 28% for pembrolizumab doses vs 4% for chemotherapy. No comparisons of different planned treatment durations are reported.</td>
                        </tr>
                        <tr>
                            <td><strong>efficacy_by_response_category</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>outcomes_after_stopping</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>safety_by_duration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>discontinuation_rate_and_reasons</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_of_durations</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>optimal_duration_conclusion</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Treatment of Advanced Metastatic Melanoma', 'publication_date_yy_mm': '2021-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Pembrolizumab versus ipilimumab in advanced melanoma <em>(Rating: 2)</em></li>
                <li>Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. <em>(Rating: 2)</em></li>
                <li>Five-Year Outcomes with Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma. <em>(Rating: 2)</em></li>
                <li>Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. <em>(Rating: 2)</em></li>
                <li>Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <em>(Rating: 2)</em></li>
                <li>Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>